A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL) Read more
A Phase 1/2 Study Of BMS-986340 As Monotherapy And In Combination With Nivolumab In Participants With Advanced Solid Tumors Read more
A Phase 2 Study Of Paxalisib (GDC-0084) In Recurrent Or Refractory Primary Central Nervous System Lymphoma (PCNSL) Read more
Phase 1 Study Of BMS-986416 (TGF-B Inhibitor) Alone And In Combination With Nivolumab In Advanced Malignant Tumors. Read more
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL) Read more
Phase 1b/2, Open-Label Dose Escalation With Expansion Study Of A ACTIVE Investigational Product In Adult Subjects With Relapsed/Refractory Primary Or Secondary Central Nervous System Lymphoma, Followed By A Phase 2 Open-Label Single Dose Level Study Of The Study Drug In Adult Subjects With Relapsed/Refractory Primary Central Nervous System Lymphoma. Read more
Treatment Of Actively Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) And Relapsed Favorable Histology Wilms Tumors (FHWT) Read more
A Phase 2 Study Of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation In Actively-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) Read more
A Phase 2 Study Of Veliparib (ABT-888) And Local Irradiation, Followed By Maintenance Veliparib And Temozolomide, In Patients With Actively Diagnosed High-Grade Glioma (HGG) Without H3 K27M Or BRAFV600 Mutations Read more
